Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic umbilical cord tissue-derived mesenchymal stromal cells ex vivo expanded
- Development stage
- Unknown
- Lead developer
- Assistance publique - Hôpitaux de Paris
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Allogeneic umbilical cord tissue-derived mesenchymal stromal cells (UC-MSCs) are an ex vivo expanded cell therapy developed by Assistance Publique - Hôpitaux de Paris (AP-HP). These cells are isolated from the Wharton's jelly of the umbilical cord and expanded under Good Manufacturing Practice (GMP) conditions. UC-MSCs possess potent immunomodulatory and anti-inflammatory properties, making them a promising candidate for treating chronic active antibody-mediated rejection (caABMR) in kidney transplant recipients. Their mechanism of action involves the secretion of paracrine factors such as indoleamine 2,3-dioxygenase (IDO), prostaglandin E2 (PGE2), and various cytokines that suppress the activation and proliferation of T-lymphocytes, B-lymphocytes, and natural killer (NK) cells. Additionally, they promote the induction and expansion of regulatory T-cells (Tregs), thereby shifting the immune balance toward graft tolerance and potentially reducing the levels of donor-specific antibodies (DSAs) that drive chronic rejection.
- Other names
- Umbilical cord-derived mesenchymal stromal cellsUC-derived MSCsAllogeneic umbilical cord-derived mesenchymal stem cellsWharton's jelly-derived mesenchymal stromal cells
Beyond the preview
Go deeper on allogeneic umbilical cord tissue-derived mesenchymal stromal cells ex vivo expanded.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic umbilical cord tissue-derived mesenchymal stromal cells ex vivo expanded.